Avalo Therapeutics (NASDAQ:AVTX) Issues Earnings Results

Avalo Therapeutics (NASDAQ:AVTX) posted its quarterly earnings data on Monday. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.18), Zacks reports.

Avalo Therapeutics Stock Performance

AVTX stock opened at $4.00 on Tuesday. Avalo Therapeutics has a 52-week low of $3.83 and a 52-week high of $16.00. The stock’s fifty day simple moving average is $6.08 and its 200-day simple moving average is $8.03.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVTX. Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Finally, Stifel Nicolaus initiated coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.